Structure Therapeutics Inc. shares fall 1.08% premarket after Seres Therapeutics announces staff cuts and cost reduction measures.

Structure Therapeutics Inc. declined 1.08% in premarket trading. The company's stock price movement is likely influenced by the recent news events related to Seres Therapeutics, Inc., which announced constructive feedback from the FDA on its Phase 2 study protocol for SER-155. However, Seres Therapeutics also announced plans to cut its workforce by 25% to extend its cash runway, which could be seen as a bearish indicator for the stock.